Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7085312 | 1.00 | MAPK1 (0.53) | MAPK1RAB9APOLBSLC40A1KDM4E | |
| SCHEMBL7088260 | 1.00 | MAPK1 (0.53) | MAPK1RAB9APOLBSLC40A1KDM4E | |
| SCHEMBL7692414 | 0.90 | POLB (0.54) | RAB9APOLBSLC40A1IDO1LMNA | |
| SCHEMBL7692413 | 0.90 | POLB (0.54) | RAB9APOLBSLC40A1IDO1LMNA | |
| SCHEMBL7695624 | 0.89 | IDO1 (0.48) | MAPK1RAB9APOLBKDM4EIDO1 | |
| SCHEMBL7695627 | 0.89 | IDO1 (0.48) | MAPK1RAB9APOLBKDM4EIDO1 | |
| SCHEMBL7693549 | 0.88 | LMNA (0.60) | POLBKDM4EIDO1LMNASMN1; SMN2 | |
| SCHEMBL7689923 | 0.88 | LMNA (0.60) | POLBKDM4EIDO1LMNASMN1; SMN2 | |
| SCHEMBL7541212 | 0.88 | PARP2 (0.47) | RAB9AKDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7677632 | 0.88 | PARP2 (0.47) | RAB9AKDM4ELMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6291499-B1 | TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE | MERCK & CO., INC. | 2001-09-18 | — | — | US | claimed |
| EP-1244639-A4 | 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2003-02-05 | — | — | EP | disclosed |
| US-6495561-B2 | TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE | MERCK & CO., INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1244639-A1 | 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020055519-A1 | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists | MERCK SHARP & DOHME CORP. | 2002-05-09 | — | — | US | disclosed |
| US-6380205-B1 | QUINAZOLINE THROUGH A C1-C4ALKYL, C1- C4ALKENYL, C1-C4ALKYNYL, C1-C4ALKOXY, AMINO, AMINOC1-C4ALKYL, HYDROXYC1-C4ALKYL, CARBONYL, CYCLOC3-C6ALKYL OR AMINOCARBONYL CHAIN, USEFUL FOR TREATMENT OF THE PAIN | MERCK & CO., INC. | 2002-04-30 | — | — | US | disclosed |
| US-20020032207-A1 | 2-Cyclohexyl quinazoline NMDA/NR2B antagonists | MERCK & CO., INC. | 2002-03-14 | — | — | US | disclosed |
| US-6291499-B1 | TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE | MERCK & CO., INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2001032634-A1 | 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055519-A1 | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists | GRIN2C, GRIN1, GRIN3A | MAPK1 1109/4885RAB9A 4572/4885POLB 4185/4885 |
| US-20020032207-A1 | 2-Cyclohexyl quinazoline NMDA/NR2B antagonists | GRIN2C, GRIN1, GRIN3A | MAPK1 987/4885RAB9A 4019/4885POLB 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.